REVIEW The Future of Breast Cancer Research in the Survivorship Field D. Soldato . L. Arecco . E. Agostinetto . M. A. Franzoi . E. Mariamidze . S. Begijanashvili . N. Brunetti . S. Spinaci . C. Solinas . I. Vaz-Luis . A. Di Meglio . M. Lambertini Received: January 6, 2023 / Accepted: March 3, 2023 / Published online: April 1, 2023 Ó The Author(s) 2023 ABSTRACT Prevalence of survivors of breast cancer has been steadily increasing in the last 20 years. Currently, more than 90% of women diagnosed with early- stage breast cancer are expected to be alive at 5 years from diagnosis thanks to early detection and breakthrough innovations in multimodal treatment strategies. Alongside this advancement in clinical outcomes, survivors of breast cancer might experience several specific challenges and present with unique needs. Survivorship trajecto- ries after diagnosis and treatment of breast cancer can be significantly impacted by long-lasting and severe treatment-related side effects, including physical problems, psychological distress, fertility issues in young women, and impaired social and D. Soldato Á L. Arecco Á M. Lambertini (&) Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy e-mail: matteo.lambertini@unige.it D. Soldato Á L. Arecco Á M. Lambertini Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy D. Soldato Á M. A. Franzoi Á I. Vaz-Luis Á A. Di Meglio Molecular Predictors and New Targets in Oncology, Institut National de la Sante et de la Recherche Medicale Unit 981, Gustave Roussy, Villejuif, France D. Soldato Á M. A. Franzoi Á I. Vaz-Luis Á A. Di Meglio Breast Cancer Unit, Medical Oncology Department, Gustave Roussy, Villejuif, France E. Agostinetto Department of Medical Oncology, Institut Jules Bordet and Universite´ Libre de Bruxelles (U.L.B.), Brussels, Belgium E. Mariamidze Department of Oncology and Hematology, Todua Clinic, Tbilisi, Georgia S. Begijanashvili Department of Clinical Oncology, American Hospital Tbilisi, Tbilisi, Georgia N. Brunetti Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy S. Spinaci Division of Breast Surgery, Villa Scassi Hospital, Genoa, Italy C. Solinas Medical Oncology, AOU Cagliari, Policlinico Duilio Casula, Monserrato, Italy Oncol Ther (2023) 11:199–229 https://doi.org/10.1007/s40487-023-00225-8